Fundraising Fox

Rhythm Pharmaceuticals

Boston, US · Founded 2013 · 6 known investors

rhythmtx.com ↗

Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity. It focuses on therapies addressing the root cause of these conditions for patients, families, and healthcare providers.

BiotechHealthtech

Founders & leadership

KG
Keith GottesdienerExecutive
BH
Bart HendersonMr. Henderson is the President and Treasurer of the Issuer.

Board

ETEdward T. Mathers
Edward T. MathersinBoard directorPartner at New Enterprise Associates (NEA)
JSJonathan Silverstein
Jonathan SilversteininBoard directorPartner at OrbiMed
NENeil Exter
Neil ExterinBoard directorRetired Partner at Third Rock Ventures
TF
Todd FoleyBoard director
CJ
Christophe JeanBoard director
DJ
David J. McGirrBoard director
DP
David P. Meeker, M.D.Board director

Investors · 6

Foresite CapitalLarkspur
HEALTHCARE ROYALTY PARTNERSNew York
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Pfizer Venture Investments$5M – $20M
OrbiMedreportedNew York · $1M – $75Mvia Jonathan Silverstein · board
Third Rock VenturesreportedBoston · $100K – $5Mvia Neil Exter · board

Reported raises · per SEC filings

Form D private placements

$60.5M disclosed across 2 rounds · 2015–2017

▶$20.5MraisedJan 2017 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David P. Meeker, M.D.Director
  • Neil ExterDirector
  • David J. McGirrDirector
  • Jonathan SilversteinDirector
  • Edward T. MathersDirector
  • Christophe JeanDirector
  • Bart HendersonExecutive Officer, Promoter
  • Todd FoleyDirector
  • Keith GottesdienerExecutive Officer, Director, Promoter
Offering amount
$40.9M
Amount sold
$20.5M
First sale
Jan 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40MraisedDec 2015 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward T. MathersDirector
  • David J. McGirrDirector
  • Jonathan SilversteinDirector
  • Keith GottesdienerExecutive Officer, Director
  • David P. Meeker, M.D.Director
  • Neil ExterDirector
  • Bart HendersonExecutive Officer
  • Todd FoleyDirector
  • Christophe JeanDirector
Offering amount
$40M
Amount sold
$40M
First sale
Aug 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock By Investing.cominvesting.com · Aug 2026Rhythm Pharmaceuticals, Inc. - MassBiomassbio.org · Aug 2026How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity - Simply Wall St Newssimplywall.st · Aug 2026Citizens raises Rhythm Pharmaceuticals price target on strong launch By Investing.cominvesting.com · Aug 2026Rhythm Pharmaceuticals reports RM-718 trial results in obesity By Investing.cominvesting.com · Aug 2026

Frequently asked questions

What does Rhythm Pharmaceuticals do?
Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity. It focuses on therapies addressing the root cause of these conditions for patients, families, and healthcare providers.
Who are Rhythm Pharmaceuticals's investors?
Rhythm Pharmaceuticals's investors include Foresite Capital, HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA), Pfizer Venture Investments, OrbiMed, Third Rock Ventures.
How much funding has Rhythm Pharmaceuticals raised?
Rhythm Pharmaceuticals has disclosed $60.5M raised across 2 rounds.
Where is Rhythm Pharmaceuticals headquartered?
Rhythm Pharmaceuticals is headquartered in Boston, US.